Gene therapy of the human retina reduction may lead to the development of AMD. In animal model, an AAV with human PEDF cDNA under the control of the CMV promoter prevented choroidal and retinal NV ( 24). The finding suggests that the AAV-mediated expression of angiostatic factors can be implemented to treat NV. This approach could be useful as an alternative to frequent injections of recombinant protein into the eye. In addition, PEDF and sFlt-1 may be able to diffuse through sclera tissue, allowing for the potential to be relatively independent of the intraocular site of administration. Gene therapy of the human retina Retinal gene therapy
Development of the human cerebral cortex during neurogenesis at mouse E10.5 to E12.5. Of the six layers found within the cortex, "layer 1 is the most superficial layer of the cortex...composed of Cajal-Retzius neurons and pyramidal cortex cells." This layer is unique in the aspect that these cells migrate to the outer edge of the cortex opposed to the migration experienced by the other 5 layers. Layer one is also characterized by expression of reelin, transcription factor T-box brain 1, and cortical migratory neuronal marker. The second and third layers, or the External Granular layer and External Pyramidal layer respectively, are formed around mouse E13.5 to